Skip to content
Screener

Jazz Pharmaceuticals JAZZ Other Non-Current Assets

Other Non-Current Assets at other companies

Amgen logo
AmgenAMGN
$12.98B+17.7%
Alkermes logo
AlkermesALKS
$62M+211%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$643K—
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$80.67M+79.9%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$26.43M+345%
XER
Xeris Biopharma Holdings, Inc.XERS
$5.03M-0.7%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.98B+165%
Enterprise value$21.71B+104%
P/S3.8×+2.3×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001232524-26-000025
Line itemMarch 31,2026December 31,2025
Goodwill1,805.01,829.3
Deferred tax assets, net907.0869.1
Deferred financing costs7.17.6
Other non-current assets94.799.0
Total assets$11,859.6$11,659.3
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable$100.0$122.1

Item 1.Financial Statements

FAQ

What is Jazz Pharmaceuticals's other non-current assets?
Jazz Pharmaceuticals (JAZZ) reported other non-current assets of $94.7M in Q1 2026.
How has Jazz Pharmaceuticals's other non-current assets changed year-over-year?
Jazz Pharmaceuticals's other non-current assets decreased by 18.7% year-over-year, from $116.52M to $94.7M.
What is the long-term trend for Jazz Pharmaceuticals's other non-current assets?
Over 5 years (2020 to 2025), Jazz Pharmaceuticals's other non-current assets has grown at a 30.9% compound annual growth rate (CAGR), from $25.72M to $99M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about Jazz Pharmaceuticals's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude